MCP1-Induced epithelial-mesenchymal transition in head and neck cancer by AKT activation

Anticancer Research

Volumn 35, Issue 6, 2015, Pages 3299-3306

  Lee, Ching Chih ^a,b   Ho, Hsu Chueh ^a,b   Su, Yu Chieh ^a,b   Lee, Moon Sing ^a,b   Hung, Shih Kai ^a,b   Lin, Chun Hsuan ^a  

^a Buddhist Dhalin Tzu Chi General Hospital   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

AKT; Epithelial mesenchymal transition; Head and neck cancer; MCP1

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN; CCL2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

ADULT; ARTICLE; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; CHEMOKINE CCL2; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84931359726     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Liao YM, Kim C and Yen Y: Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol 3: 22, 2011.
4. Tabuchi K, Nakayama M, Nishimura B, Hayashi K and Hara A: Early detection of nasopharyngeal carcinoma. Int J Otolaryngol 2011: 638058, 2011.
5. National Comprehensive Cancer Network Guidelines Version 2.2014 2014. http://www.nccn.org/default.aspx
6. Cripps C, Winquist E, Devries MC, Stys-Norman D and Gilbert R: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 17: 37-48, 2010.
7. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation and cancer. Cell 140: 883-899, 2010.
8. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C and Flavell RA: Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13: 759-771, 2013.
9. Ren JL, Pan JS, Lu YP, Sun P and Han J: Inflammatory signaling and cellular senescence. Cell Signal 21: 378-383, 2009.
10. Pietras K and Ostman A: Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316: 1324-1331, 2010.
11. McAllister SS and Weinberg RA: Tumor-host interactions: a far-reaching relationship. J Clin Oncol 28: 4022-4028, 2010.
12. Hanahan D and Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-322, 2012.
13. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis and survival in human breast cancer. Clin Cancer Res 6: 3282-3289, 2000.
14. Deshmane SL, Kremlev S, Amini S and Sawaya BE: Monocyte chemoattractant protein-1 (MCP1): an overview. J Interferon Cytokine Res 29: 313-326, 2009.
15. Youngs SJ, Ali SA, Taub DD and Rees RC: Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71: 257-266, 1997.
16. Ji WT, Chen HR, Lin CH, Lee JW and Lee CC: Monocyte chemotactic protein 1 (MCP1) modulates pro-survival signaling to promote progression of head and neck squamous cell carcinoma. PLoS One 9: e88952, 2014.
17. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T and Bentires-Alj M: Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515: 130-133, 2014.
18. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
19. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: American joint committee on cancer-cancer staging mannul. 7th ed. Spriinger 2010.
20. Lee CC, Ho HC, Lee MS, Hung SK, Yu CC and Su YC: Expression of haptoglobin predicts recurrence in head and neck squamous cell carcinoma. Clin Chim Acta 411: 1116-1121, 2010.
21. Tse KP, Tsang NM, Chen KD, Li HP, Liang Y, Hsueh C, Chang KP, Yu JS, Hao SP, Hsieh LL and Chang YS: MCP1 Promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res 13: 6320-6326, 2007.
22. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL and Wu JC: Comprehensive analysis of the independent effect of TWIST and SNAIL in promoting metastasis of hepatocellular carcinoma. Hepatology 50: 1464-1474, 2009.
23. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by HIF1α promotes metastasis. Nat Cell Biol 10: 295-305, 2008.
24. da Silva SD, Morand GB, Alobaid FA, Hier MP, Mlynarek AM, Alaoui-Jamali MA and Kowalski LP: Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma. Clin Exp Metastasis 32: 55-63, 2015.
25. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
26. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: TWIST, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.
27. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
28. Klymkowsky MW and Savagner P: Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 174: 1588-1593, 2009.
29. Tlsty TD and Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119-150, 2006.
30. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G and Gruden G: Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51: 198-207, 2008.
31. Park J, Ryu D-R, Li JJ, Jung D-S, Kwak S-J, Lee SH, Yoo T-H, Han SH, Lee JE, Kim DK, Moon SJ, Kim K, Han DS and Kang S-W: MCP1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells 2008.
32. Lee SH, Kang HY, Kim KS, Nam BY, Paeng J, Kim S, Li JJ, Park JT, Kim DK, Han SH, Yoo TH and Kang SW: The monocyte chemoattractant protein-1 (MCP1)/CCR2 system is involved in peritoneal dialysis-related epithelial-mesenchymal transition of peritoneal mesothelial cells. Lab Invest 92: 1698-1711, 2012.
33. van Golen KL, Ying C, Sequeira L, Dubyk CW, Reisenberger T, Chinnaiyan AM, Pienta KJ and Loberg RD: CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase RAC. J Cell Biochem 104: 1587-1597, 2008.
34. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M and Ben-Baruch A: Inflammatory mediators in breast cancer: coordinated expression of TNFα and IL-1β with CCL2 and CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11: 130, 2011.
35. Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ and Chang C: Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med 5: 1383-1401, 2013.
36. Li MQ, Li HP, Meng YH, Wang XQ, Zhu XY, Mei J and Li DJ: Chemokine CCL2 enhances survival and invasiveness of endometrial stromal cells in an autocrine manner by activating AKT and MAPK/ERK1/2 signal pathway. Fertil Steril 97: 919-929, 2012.
37. Yoshimura T, Howard OM, Ito T, Kuwabara M, Matsukawa A, Chen K, Liu Y, Liu M, Oppenheim JJ and Wang JM: Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells. PLoS One 8: e58791, 2013.
38. Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW and Sweeney CJ: Elevated IL8, TNFα and MCP1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate 74: 820-828, 2014.
39. Keller ET, Chang C and Ershler WB: Inhibition of NFkappaB activity through maintenance of IκBα levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 271: 26267-26275, 1996.
40. Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, Berns B, Seetharam S, de Bono JS and Tolcher AW: A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol 71: 1041-1050, 2013.
41. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, Dawkins F and de Bono JS: Phase II study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 31: 760-768, 2013.
42. Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J and Calvo E: Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase Ib study. Target Oncol 2014.
43. Kane SV, Gupta M, Kakade AC and A DC: Depth of invasion is the most significant histological predictor of subclinical cervical lymph node metastasis in early squamous carcinomas of the oral cavity. Eur J Surg Oncol 32: 795-803, 2006.
44. Goerkem M, Braun J and Stoeckli SJ: Evaluation of clinical and histomorphological parameters as potential predictors of occult metastases in sentinel lymph nodes of early squamous cell carcinoma of the oral cavity. Ann Surg Oncol 17: 527-535, 2010.
45. Huang TT, Gonzales CB, Gu F, Hsu YT, Jadhav RR, Wang CM, Redding SW, Tseng CE, Lee CC, Thompson IM, Chen HR, Huang TH and Kirma NB: Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis 34: 1717-1727, 2013.